The Wellcome Trust Strategic Award in Medical Mycology and Fungal Immunology is a unique investment that aimed to bolster capacity, training and research activity throughout the UK. This article summarises the rationale for collective collaboration of multiple institutions to achieve synergies and address a common medical problem.
Background about Fungal Infections
Medical mycology is one of many areas in the biomedical sciences that is served by a small, dispersed community that is below critical mass. Whilst funders may be sympathetic to the challenges in stimulating growth and research activity in such areas, they may lack appropriate funding mechanisms to create synergies and draw research communities together. This article reports on the outputs and achieve- Fungi are critical to the function of the world's ecosystem, and many species provide vital chemicals, drugs [ 8 2 _ T D $ D I F F ] and food products. As model systems, fungi have been the organisms of choice for a dozen Nobel laureates to illustrate fundamental principles in genetics and cell biology. Some fungi are known for their ability to cause skin infections (ringworm, athlete's foot, dandruff etc.), whereas others are a feared cause of fatal human infections [1] . Deaths per annum due to fungal infections are greater than the global mortality due to malaria, breast or prostate cancer, and are similar to that inflicted by tuberculosis (TB) or HIV [2] ii .
A systematic analysis of the fungal disease burden in 2017, covering 883 million people in 14 countries, revealed that an average of 2% of people have a serious fungal infection [3] . In many of these countries, the figures can only be estimates, due to inadequate or late diagnosis and a lack of effective reporting systems, suggesting a significantly higher actual burden. Current global estimates suggest that over a million people die of fungal infections, 10 million suffer severe fungal allergy, 100 million women are victims of recurrent vulvovaginal infections annually, and more than a billion people suffer skin infections [2] ii .
There are no vaccines or immunotherapies for mycoses and only a limited arsenal of antifungal drugs to treat infections, with invasive infections often diagnosed too late to save the patient.
Building Critical Mass
In the UK, between 1997 and 2010, total investment in all infectious disease research was £2.6 billion [4] , but only 2% of this was spent on medical mycology research [5] . 
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and Edinburgh to present showcase events for eukaryotic medical microbiology that led to cross-disciplinary analyses, for example, drug resistance in eukaryotic pathogens [6] .
Outputs and Impact
Since 2012 the consortium has generated more than 250 communications The WTSA-MMFI was conceived as a unique approach to tackling the major global impact of invasive fungal infection by harnessing collective medical mycology expertise in the UK to create synergies in research and training activities. As a result, the UK medical mycology research community has become more firmly integrated. Capacity in this critical sector has grown, and public awareness of medical mycology issues has increased. Invasive fungal infections continue to rise, and organisations such as agricultural use of azoles may be exacerbating the spread of drug-resistant Aspergillus species, and emerging multidrug-resistant species, such as Candida auris, are fast becoming major health threats [6] [7] [8] . These factors emphasise the need for high-quality medical mycology research, with strategic and targeted modes of funding, to enable capacity development and research interactions to counter these global threats. 
